March 13, 2018 / 11:30 AM / 3 months ago

BRIEF-Aeglea Biotherapeutics Q4 Revenue $1.5 Mln Vs $1.2 Mln

* AEGLEA BIOTHERAPEUTICS PROVIDES KEY CLINICAL DATA UPDATE FROM PHASE 1/2 TRIAL IN ARGINASE 1 DEFICIENCY AND REPORTS Q4 AND FULL YEAR 2017 FINANCIAL RESULTS

* Q4 REVENUE VIEW $1.2 MILLION — THOMSON REUTERS I/B/E/S

* ‍REPEAT DOSES OF COMPANY’S PEGZILARGINASE PRODUCES MARKED AND SUSTAINED REDUCTIONS IN PLASMA ARGININE LEVELS​

* ‍ACCOMPANYING REDUCTIONS IN OTHER RELATED GUANIDINO COMPOUNDS ALSO SEEN IN STUDY​

* ‍EXPECTS TO REPORT PEDIATRIC AND ADULT REPEAT DOSE DATA IN PATIENTS WITH ARGINASE 1 DEFICIENCY IN Q3 2018​

* AEGLEA BIO - ‍AS OF DEC 31, 2017, HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $50.3 MILLION​

* AEGLEA BIO THERAPEUTICS - BASED ON CURRENT OPERATING PLAN, BELIEVES HAS SUFFICIENT CAPITAL RESOURCES TO FUND ANTICIPATED OPERATIONS THROUGH Q3 2019

* NET LOSS TOTALED $6.5 MILLION AND $5.5 MILLION FOR Q4 OF 2017 AND 2016, RESPECTIVELY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below